Karyopharm Therapeutics Boosts Talent Acquisition with New Restricted Stock Unit Grants

Karyopharm Therapeutics Strengthens Workforce with New Inducement Grants

On November 3, 2025, Karyopharm Therapeutics Inc. announced the grant of 800 restricted stock units (RSUs) to a newly hired employee as part of its ongoing commitment to attracting top talent in the competitive pharmaceutical sector. This award, effective October 31, 2025, is intended to align with the company’s 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a three-year period, with one-third of the shares vesting on each anniversary of the grant date, contingent upon the employee’s continued service at Karyopharm. This strategic move underscores Karyopharm’s focus on fostering a skilled workforce that can drive innovation and support its mission in the oncology field.

Karyopharm Therapeutics is recognized as a pioneer in the development of oral therapies targeting nuclear export dysregulation, which plays a critical role in cancer progression. The company’s flagship product, XPOVIO® (selinexor), is a groundbreaking oral exportin 1 (XPO1) inhibitor that has gained U.S. approval for three oncology indications and is available in over 50 international markets, including the European Union and China as NEXPOVIO®. This product demonstrates Karyopharm’s dedication to providing cutting-edge treatments for patients grappling with various malignancies, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). By strengthening its workforce, Karyopharm aims to enhance its research and development capabilities to address high unmet medical needs in cancer therapeutics.

The company's proactive approach to talent acquisition reflects its commitment to advancing cancer treatment and improving patient outcomes. Karyopharm’s ongoing investment in human capital is essential for maintaining its competitive edge in an industry characterized by rapid technological advancements and evolving therapeutic landscapes. By aligning employee incentives with the company’s long-term goals, Karyopharm reinforces its belief in the resilience of cancer patients and its mission to develop innovative solutions for their treatment.

In addition to its focus on workforce expansion, Karyopharm continues to make strides in its pipeline development. The company is dedicated to addressing the unmet medical needs across various cancers, ensuring a robust portfolio that meets the challenges of today's oncology landscape. For more updates on Karyopharm's initiatives and pipeline developments, stakeholders can visit the company’s website or follow them on LinkedIn and X at @Karyopharm.